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Abstract
Aims: A normal tissue complication probability (NTCP) model of severe acute mucositis would be highly useful to guide clinical decision making and inform
radiotherapy planning. We aimed to improve upon our previous model by using a novel oral mucosal surface organ at risk (OAR) in place of an oral cavity OAR.
Materials and methods: Predictive models of severe acute mucositis were generated using radiotherapy dose to the oral cavity OAR or mucosal surface OAR and
clinical data. Penalised logistic regression and random forest classiﬁcation (RFC) models were generated for both OARs and compared. Internal validation was
carried out with 100-iteration stratiﬁed shufﬂe split cross-validation, using multiple metrics to assess different aspects of model performance. Associations
between treatment covariates and severe mucositis were explored using RFC feature importance.
Results: Penalised logistic regression and RFC models using the oral cavity OAR performed at least as well as the models using mucosal surface OAR. Associations
between dose metrics and severe mucositis were similar between the mucosal surface and oral cavity models. The volumes of oral cavity or mucosal surface
receiving intermediate and high doses were most strongly associated with severe mucositis.
Conclusions: The simpler oral cavity OAR should be preferred over the mucosal surface OAR for NTCP modelling of severe mucositis. We recommend minimising
the volume of mucosa receiving intermediate and high doses, where possible.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Mucositis is a common and important acute toxicity of
head and neck radiotherapy, which may result in pain,
dysphagia [1] andweight loss, and, hence, reduced quality of
life [2,3]. Mucositis may lead to missed treatment fractions
[4] and is frequently dose limiting in dose-escalation and
accelerated fractionation regimens designed to improve
tumour control [5e7]. Furthermore, severe acute reactions
have been implicated in the subsequent development of
‘late’ radiation toxicity [8e10]. A normal tissue complicationAuthor for correspondence: J.A. Dean, Joint Department of Physics at The
Institute of Cancer Research and The Royal Marsden NHS Foundation Trust,
London SM2 5NG, UK. Tel: þ44-208-9156223; Fax: þ44-208-6433812.
E-mail address: jamie.dean@icr.ac.uk (J.A. Dean).
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cient predictive performance, could be used for clinical
decision-support [11]. Associations between radiotherapy
dose metrics and mucositis could inform changes to the
radiotherapy planning dose objectives to reduce the inci-
dence of severemucositis. It has previously been shown that
intensity-modulated radiotherapy can be used to spare the
oral mucosa in oropharyngeal radiotherapy patients [12].
Our group has previously generated and internally vali-
dated an acute mucositis NTCP model, with modest-to-
good discriminative ability (mean area under the receiver
operating characteristic curve [AUC] ¼ 0.71, standard
deviation ¼ 0.09 on internal validation) [13]. The below-
perfect predictive performance was attributed to limita-
tions of the organ at risk (OAR) segmentation, limitations of
the toxicity scoring instrument and not having data onis is an open access article under the CC BY license (http://creativecommons.
tion Probability (NTCP) Modelling of Severe Acute Mucositis using a
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these can be addressed retrospectively. We hypothesised
that the discriminative ability could be improved through a
more accurate description of the dose distribution to the
oral mucosal surfaces, which were previously described by
the oral cavity volume contours (OCC) method [14]. The
OCC OAR predominantly describes the dose to the muscu-
lature of the tongue and ﬂoor of mouth, which are not ex-
pected to be relevant for mucositis, and does not
incorporate the buccal mucosa or mucosa of the lips. We,
therefore, developed a novel oral mucosal surface contours
(MSC) OAR structure that includes the mucosal surfaces of
the oral cavity and excludes the musculature of the tongue
and ﬂoor of mouth [15]. It was expected that this novel OAR
would be more relevant to NTCP modelling of mucositis. To
aid implementation of this OAR to a large cohort of patients,
we showed that the segmentation of this structure could be
fully automated using atlas-based segmentation [16].
The aims of this study were to: (i) improve the discrim-
inative ability of our, previously reported, acute mucositis
NTCP model [13] and (ii) gain greater insight into the
radiotherapy doseeresponse relationship of the oral mu-
cosa, through the application of our novel, automatically
segmented MSC structure [15,16].Materials and Methods
Patient Data
A cohort of 351 head and neck radiotherapy patients,
enrolled in six different clinical trials [17e23] (with insti-
tutional review board approval and signed patient consent;
summarised in Appendix A), diverse in terms of primary
disease site, radiotherapy treatment technique and use of
concurrent chemotherapy, was used. The prescribed dose to
the primary planning target volume was either 65 Gy in 30
fractions, 60 Gy in 30 fractions, 67.2 Gy in 28 fractions or
63 Gy in 28 fractions (described in Appendix A). Toxicity
was consistently scored for all studies using the mucositis
score from the Common Terminology Criteria for Adverse
Events (CTCAE) versions 2 (mucositis due to radiation) [24]
or 3 (mucositis/stomatitis [clinical examination]) [25] in-
struments, which are near equivalent. Toxicities were
recorded prospectively before the start of radiotherapy,
weekly during radiotherapy, and at 1e4 and 8 weeks after
radiotherapy. The toxicity end point of interest chosen for
analysis was the maximum reported mucositis grade. Pa-
tients were dichotomised into severe (maximum toxicity
score of grade 3 or worse) and non-severe (maximum
toxicity score of less than grade 3) mucositis. Patients with
baseline toxicity or any missing toxicity scores and a
maximum score below 3 were excluded from the analysis.
Ourmissing data handling strategy is discussed in Appendix
B. Complete DICOM radiotherapy data were available for
351 patients. After removing patients who had bothmissing
toxicity data and a maximum toxicity of grade 2 or lower,
182 patients were available for analysis. MSC atlas-based
segmentation failed for three patients (for no obviousPlease cite this article in press as: Dean JA, et al., Normal Tissue Complica
Novel Oral Mucosal Surface Organ at Risk, Clinical Oncology (2016), httpreasons), so these were excluded from the analysis, leaving
179. Severe mucositis incidence was 74%. Note that
excluding the patients removed due to missing toxicity data
skews the incidence values to higher than the actual
incidences.
Induction chemotherapy (n ¼ 89), concurrent chemo-
therapy regimen (cisplatin [n ¼ 64], carboplatin [n ¼ 10],
one cycle of cisplatin followed by one cycle of carboplatin
[n¼ 6] or none [n¼ 99]; administered in two cycles, on days
1 and 29 of radiotherapy), deﬁnitive (n ¼ 149) versus
postoperative radiotherapy, age (median ¼ 57 years,
range ¼ 17e88 years), gender (nmale ¼ 114) and primary
disease site (nasopharynx [n ¼ 18], oropharynx [n ¼ 100],
hypopharynx/larynx [n ¼ 18], unknown primary [n ¼ 8] or
parotid gland [n ¼ 35]) were also included as covariates in
the models. Unilateral versus bilateral irradiation was not
explicitly included as a covariate in the models as it corre-
lates perfectly with parotid gland primary disease site.Radiotherapy Dose Data
The oral mucosa was contoured on computed tomogra-
phy using two different techniques: the current guidelines
(OCC) method [14] and our novel MSC technique [15,16].
Mucositis of the portion of the pharyngeal mucosa visible
on clinical examination was included in the scoring of
mucositis. Therefore, the pharyngeal mucosa was manually
delineated from the roof of the nasopharynx to the level of
the inferior border of the oral mucosa structure (OCC or
MSC as appropriate) and combined with the OCC or MSC
structure (denoted OCC-PM and MSC-PM). The inferior ex-
tents of the OCC and MSC structures were very similar.
Figure 1 shows an example of these structures. Clinical
oncologists carried out the OCC and PM contouring,
following the same guidelines, using the RayStation
research version 4.6.100.12 treatment planning system
(RaySearch Laboratories AB, Stockholm, Sweden). MSC
contouring was carried out manually for 41 patients (those
included in the atlas and test cohort in [16]). For the
remaining patients the MSC was delineated fully automat-
ically. The automatically generated OARs were visually
assessed for gross errors. Three patients were excluded due
to failure of the automatic segmentation, as previously
described in the patient data section. The techniques for
manual and automatic MSC segmentation are described in
[16].
The physical dose distribution was converted to the
fractional dose distribution (physical dose delivered in each
fraction), as recommended for modelling of acute toxicity
by Tucker et al. [26]. The fractional dose distribution was
described by the dose-volume histogram (DVH) in 20 cGy
intervals from 20 to 260 cGy per fraction. There may be
regional variations in radiosensitivity across the oral mu-
cosa that cannot be detected by describing the dose distri-
butions using only DVHs. For example, keratinised areas of
the oral mucosa might be expected to be associated with
lower mucositis scores [27] than non-keratinised regions of
the oral mucosa [28]. Therefore, three-dimensionaltion Probability (NTCP) Modelling of Severe Acute Mucositis using a
://dx.doi.org/10.1016/j.clon.2016.12.001
Fig 1. Example of oral cavity (OCC; blue), mucosal surface (MSC; green) and pharyngeal mucosa (PM; red) contours.
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tribution of the dose were calculated using the expression
habc ¼
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(2)
where x, y and z are the voxel coordinates, Dðx; y; zÞ is the
dose delivered to the voxel with coordinates ðx; y; zÞ,
Iðx; y; zÞ is an identity function, which takes a value of 1 if
the voxel belongs to the OAR and 0 if it does not, and ðx; y; zÞ
is the centre of gravity of the OAR. The moments are
translational and scale invariant. The lefteright symmetry is
accounted for by taking the modulus of the ðx xÞ term.
Therefore, the moments in the lefteright direction describe
how lateralised or centralised the dose is. The different
three-dimensional moment invariants describe the centre
of mass (h001, h010, h100, h011, h101, h110, h111), spread (h002,
h020, h200) and skewness (h003, h030, h003) of the dose dis-
tribution in the three orthogonal directions (lefteright,
anterioreposterior, superioreinferior) within each struc-
ture. These allow for regional variations in radiosensitivity
to be probed. These would manifest as differences in one or
more of the moment invariants between patients who
experienced severe mucositis and those who did not. An
example of the three-dimensional moment invariants is
shown in Appendix C. The dose metrics were used as
covariates in the statistical modelling.
Statistical Analysis
All radiotherapy dose and clinical covariates were
transformed to standardised scores (mean ¼ 0, standard
deviation ¼ 1) to avoid scale-related feature dominance. To
determine which of the structures resulted in the highest
discriminative ability, penalised logistic regression (PLR)
[30,31] models were generated and internally validated forPlease cite this article in press as: Dean JA, et al., Normal Tissue Complica
Novel Oral Mucosal Surface Organ at Risk, Clinical Oncology (2016), httpboth of the structures (OCC-PM and MSC-PM). PLR models
reduce the regression coefﬁcients to reduce the risk of
overﬁtting the data. Models were generated with (spa) and
without (sta) the addition of the spatial dose metrics.
During model generation, the samples of each outcome
class were over- or undersampled according to weights
inversely proportional to the class frequencies in the
training data to account for unbalanced numbers of pa-
tients experiencing severe and non-severe mucositis.
Model hyper-parameter tuning was carried out using a
cross-validated grid-search with 100 iterations of stratiﬁed
shufﬂe split cross-validationwith a train/test split of 80/20.
The possible hyper-parameters over which the cross-
validated grid-searchers were carried out are given in
Appendix D. To establish whether the discriminative abil-
ity could be improved through the use of a more complex
model, random forest classiﬁcation (RFC) [32] models were
also generated (our choice of RFC models is discussed
in [13]).
The generalisability of the models (aim i) was measured
through internal validation. Randomly splitting datasets
into a development and independent validation sample,
although often carried out, provides little additional in-
formation over internal validation and increases the risk of
bias in small datasets [33,34]. Therefore, all available data
were used for generating and internally validating the
models. External validation of any promising models
should be carried out in the future. Internal validation used
a nested 100-iteration stratiﬁed shufﬂe split cross-
validation, with a train/test split of 80/20, incorporating
covariate transformation to standardised scores and hyper-
parameter tuning with a ﬁve-fold cross-validated grid-
search within each iteration to give unbiased error esti-
mates. AUC was used as the scoring metric for the grid-
search. The predictive performance of the models was
assessed using AUC to measure discrimination, Brier score
[35] to measure overall model performance and log loss
[36] to assess the model probability estimates. The slope
and intercept of a logistic regression model of the actual
mucositis outcomes against the predicted probabilities of
severe mucositis made by the models was used to measuretion Probability (NTCP) Modelling of Severe Acute Mucositis using a
://dx.doi.org/10.1016/j.clon.2016.12.001
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calibration metrics and their 95% conﬁdence intervals were
used for model comparisons. Selecting models based on
formal statistical testing of differences in AUC is inappro-
priate in this context as this metric gives equal importance
weighting to sensitivity and speciﬁcity, which does not
align with clinical objectives.
To determine associations between treatment factors
and mucositis severity (aim ii), the RFCOCC-PM,spa and
RFCMSC-PM,spa model Gini feature importance values were
bootstrapped with 2000 replicates. We have previously
shown that this approach is more suitable than the, often
used, logistic regression coefﬁcients, in the context of highly
correlated radiotherapy dose-volume metrics [13]. The
statistical analysis was carried out using the Python version
2.7.9 programming language [39] and Pandas version 0.18
[40] and Scikit-learn version 0.17 [41] modules.Fig 2. Summary of dose-volume data for (a) the oral cavity contours
and pharyngeal mucosa organ at risk (OCC-PM) structure and (b) the
mucosal surface contours and pharyngeal mucosa organ at risk (MSC-
PM) structure, grouped by peak mucositis severity. The lines repre-
sent the group medians and the error bars represent the boot-
strapped 95 percentile conﬁdence intervals on the medians. It should
be noted that the volumes are measured at the same fractional dose
values for both outcome groups. However, there is an artiﬁcial offset
to aid visualisation of overlapping error bars.Results
The DVH data and correlation matrix for the data are
summarised in Figure 2 and Appendix E, respectively, and
show a relationship between the DVH and mucositis
severity for both OARs. The correlationmatrix indicates that
the DVH-based covariates were highly correlated, both
within the same OAR and between the two different OARs.
Addressing the ﬁrst aim of generating models to make ac-
curate predictions of mucositis severity, the metrics
describing the predictive performance of the models are
shown in Table 1. The discriminative abilities of all of the
models were modest-to-good. For all models the use of the
MSC-PM OAR did not lead to an improvement in predictive
performance compared with the corresponding model us-
ing the OCC-PM OAR. For both structures (OCC-PM and
MSC-PM) and both types of model (PLR and RFC), the
addition of the spatial dose metrics did not result in
improved model performance, as assessed by any of the
metrics. The RFC models were better-calibrated (calibration
slope closer to 1 and calibration intercept closer to 0) and
provided better probability estimates (lower log loss) and
overall performance (lower Brier score) than the PLR
models. However, they had slightly worse discrimination
(lower AUC). Preliminary analysis indicated that excluding
the pharyngeal mucosa from the OARs did not substantially
alter any of the results.
The regression coefﬁcients, means and standard de-
viations for the covariates in the PLROCC-PM,sta and PLRMSC-
PM,sta models are given in Table 2. These values are required
to use the models. It should be noted that the regression
coefﬁcients of PLR models, like other linear models, are
unstable in the presence of multicollinearity. This does not
prevent them from being used tomake accurate predictions
of patient toxicity outcomes, but does mean that the
regression coefﬁcients should not be used to infer associa-
tions between the correlated dose metrics and severe
mucositis. RFC models were used for this purpose as they
are more robust to multicollinearity.Please cite this article in press as: Dean JA, et al., Normal Tissue Complica
Novel Oral Mucosal Surface Organ at Risk, Clinical Oncology (2016), httpRegarding the second aim of establishing associations
between treatment covariates, such as radiotherapy dose
metrics, and mucositis severity, the feature importance
values of the RFC models are displayed in Figure 3. These
indicate that, when the OCC-PMwas considered as the OAR,
the feature importance of the dose-volume metrics
increased with increasing dose, peaking at V180 and V220.
The spatial dose metric with the highest feature importance
was h010, which represents the centre of mass of the dose in
the anterioreposterior direction. When the MSC-PM was
considered as the OAR, V160eV220 had the highest feature
importance values. A sharp increase in feature importance
was observed between V120 and V160. Feature importance
declined from V220 to V260. The decline in feature impor-
tance does not indicate a reduction in biological effect at
these dose levels, rather it is due to a lack of variance intion Probability (NTCP) Modelling of Severe Acute Mucositis using a
://dx.doi.org/10.1016/j.clon.2016.12.001
Table 1
Measures of predictive performance of models on internal validation
Model Hyper- parameters Mean (standard deviation)
AUC Log loss Brier score Calibration slope Calibration
intercept
PLROCC-PM,sta Penalty ¼ l1; C ¼ 0.1 0.71 (0.10) 0.66 (0.04) 0.23 (0.02) 11.3 (11.2) e4.4 (5.5)
PLRMSC-PM,sta Penalty ¼ l2; C ¼ 0.001 0.70 (0.09) 0.66 (0.04) 0.23 (0.01) 14.5 (12.1) e6.0 (5.9)
PLROCC-PM,spa Penalty ¼ l1; C ¼ 0.1 0.71 (0.11) 0.67 (0.05) 0.23 (0.02) 10.7 (10.9) e4.1 (5.4)
PLRMSC-PM,spa Penalty ¼ l1; C ¼ 0.1 0.69 (0.09) 0.67 (0.05) 0.23 (0.02) 11.1 (10.3) e4.3 (5.0)
RFCOCC-PM,sta Maximum depth ¼ 5,
maximum features ¼ square root
0.69 (0.09) 0.56 (0.08) 0.19 (0.03) 3.3 (2.1) e1.0 (1.3)
RFCMSC-PM,sta Maximum depth ¼ 5,
maximum features ¼ square root
0.68 (0.08) 0.56 (0.06) 0.18 (0.02) 3.4 (1.8) e1.1 (1.1)
RFCOCC-PM,spa Maximum depth ¼ 5,
maximum features ¼ square root
0.67 (0.10) 0.55 (0.07) 0.18 (0.03) 3.7 (2.6) e1.4 (1.8)
RFCMSC-PM,spa Maximum depth ¼ 5,
maximum features ¼ square root
0.67 (0.08) 0.56 (0.07) 0.19 (0.03) 3.4 (2.1) e1.2 (1.4)
PLR, penalised logistic regression; RFC, random forest classiﬁcation; l1, LASSO regularisation; l2, ridge regularisation; OCC-PM, combined
oral cavity and pharyngeal mucosa (extending inferiorly to level of inferior border of oral cavity) contours; MSC-PM, combined oral mucosal
surfaces and pharyngeal mucosa (extending inferiorly to level of inferior border of oral mucosal surfaces) contours; sta, standard model
(dose-volume metrics only); spa, spatial model (dose-volume plus spatial dose metrics).
Table 2
Regression coefﬁcients and covariate transformation values for PLROCC-PM,sta and PLRMSC-PM,sta models
Covariate Regression coefﬁcient Mean Standard deviation
PLROCC-PM,sta PLRMSC-PM,sta
Intercept 0.000 0.002 e e
deﬁnitiveRT 0.000 e0.009 0.832 0.374
Male 0.000 0.007 0.637 0.481
Age 0.000 e0.006 56.7 11.9
indChemo 0.000 0.010 0.497 0.500
noConChemo 0.000 e0.012 0.553 0.497
Cisplatin 0.000 0.013 0.358 0.479
Carboplatin 0.000 0.002 0.0559 0.230
cisCarbo 0.000 e0.004 0.0335 0.180
hypopharynx/larynx 0.000 0.005 0.101 0.301
Oropharynx 0.000 0.021 0.559 0.497
Nasopharynx 0.000 0.005 0.101 0.301
unknown primary e0.012 e0.011 0.0447 0.207
Parotid e0.243 e0.028 0.196 0.397
V020 0.000 e0.006 96.2/91.8 9.72/16.1
V040 0.000 e0.004 94.6/88.3 12.2/18.3
V060 0.000 0.004 92.6/83.1 14.1/20.0
V080 0.000 0.011 88.2/76.6 17.1/21.7
V100 0.000 0.017 82.5/70.1 21.3/22.4
V120 0.000 0.020 76.8/63.4 24.4/22.3
V140 0.000 0.021 70.9/56.8 25.9/21.6
V160 0.000 0.023 64.5/50.0 26.5/20.4
V180 0.201 0.022 57.2/43.2 26.4/19.4
V200 0.000 0.023 47.4/35.2 27.1/19.6
V220 0.250 0.025 12.4/11.1 11.4/9.41
V240 0.000 0.003 0.170/0.303 1.24/2.16
V260 0.000 0.000 0.000/0.000 1.00/1.00
The regression coefﬁcients of many of the covariates in the PLROCC-PM,sta model were set to 0 by the LASSO penalisation. Vx, volume of organ
receiving x cGy of radiation per fraction. Mean and standard deviation for dose-volume metrics, Vx are given as OCC-PM/MSC-PM.
deﬁnitiveRT, deﬁnitive radiation therapy (versus postoperative radiation therapy); indChemo, induction chemotherapy; noConChemo, no
concurrent chemotherapy; cisCarbo, one cycle of cisplatin followed by one cycle of carboplatin.
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Fig 3. Random forest classiﬁcation feature importance values for the (a) RFCOCC-PM,spa and (b) RFCMSC-PM,spa models, bootstrapped with 2000
replicates. The whiskers show the 95 percentile conﬁdence intervals.
J.A. Dean et al. / Clinical Oncology xxx (2016) 1e116these covariates in our dataset (as the values of these dose
metrics approach zero for all patients). The spatial dose
metric with the highest feature importance was h110, which
represents the centre of mass of the dose in the diagonal
lefterighteanterioreposterior direction. Age was the clin-
ical covariate with the highest feature importance in both
models. However, it should be noted that this may be
related to the fact that RFC feature importance can be arti-
ﬁcially inﬂated for covariates having a large number of
different values [42]. Age was negatively correlated with
severe mucositis on univariable (Appendix E) andPlease cite this article in press as: Dean JA, et al., Normal Tissue Complica
Novel Oral Mucosal Surface Organ at Risk, Clinical Oncology (2016), httpmultivariable (Table 2; small negative regression coefﬁ-
cient) analysis.Discussion
We generated models of severe acute mucositis using a
novel MSC OAR and spatial dose metrics with the aims of:
(i) improving the ability of NTCP models to predict which
patients would experience severe mucositis and (ii)
improving our understanding of the link between thetion Probability (NTCP) Modelling of Severe Acute Mucositis using a
://dx.doi.org/10.1016/j.clon.2016.12.001
J.A. Dean et al. / Clinical Oncology xxx (2016) 1e11 7radiotherapy dose distribution and severe mucositis. We
determined that using our novel MSC OAR to describe the
dose distribution did not improve predictive performance
over our previously used OCC OAR. This is probably due to
the fact that, although the dose metrics between the two
contouring approaches were different, they were highly
correlated (Appendix E). We therefore recommend the use
of the simpler OCC OAR for developing mucositis severity
(not including spatial extent) clinical decision-support
tools. The RFC models should be favoured over the PLR
models for their ability to make superior probability pre-
dictions and only slightly inferior discrimination. More-
over, we established that adding spatial dose metrics,
describing the centre of mass, spread and skewness of the
dose distribution in three dimensions, did not improve the
predictive performance of the models, compared with
models using only dose-volume-based descriptors of the
radiotherapy dose distribution. This is probably due to the
fact that the CTCAE mucositis scoring instrument used in
the clinical trials does not capture information on the
location or extent of mucositis. We suggest that in-
vestigators consider the use of a mucositis scoring in-
strument sensitive to the spatial extent of mucositis, such
as the Oral Mucositis Assessment Scale [43], for the study
of radiation-induced mucositis in the future. We expect
that the MSC OAR and spatial dose metrics may improve
the discriminative ability of models of mucositis extent.
However, this requires evaluation.
With regards to the second aim, we determined that the
volumes of oral mucosa receiving high and intermediate
doses (about 160 cGy per fraction and higher) were the
treatment covariates with the strongest associations with
mucositis severity. Although this is intuitive, mean oral
cavity dose is currently used as an objective in radiotherapy
planning protocols (for example in the RTOG 0912, RTOG
0920 and RTOG 1216 trials). The mean dose gives equal
importance weighting to low doses as high doses. We
recommend that protocols attempt to reduce the volumes
of oral mucosa receiving high and intermediate dose levels
instead.
Our group has previously published models of severe
acute mucositis [13,44], which we attempted to improve
upon in this study. We recommend our previous model [13]
be favoured over the models in this study, as it was not
outperformed by any of those described here. To the best of
our knowledge, no other (internally or externally) validated
models of severe acute mucositis, allowing individualised
risk estimates to be made (aim i), have been published in
the intensity-modulated radiotherapy era. Conversely,
several studies have focussed on establishing the covariates
that were most strongly associated with toxicity (aim ii). In
support of our ﬁndings of associations between radio-
therapy dose and mucositis, a small prospective study
showed that cumulative point doses of 32 Gy or lower (with
varying fractionations) were associated with minimal
mucositis at those points [27] and a larger study found as-
sociations between weekly doses of 10.1 Gy and severe
mucositis [45]. Also, a small randomised trial has shown the
beneﬁts of sparing the oral mucosa outside of the planningPlease cite this article in press as: Dean JA, et al., Normal Tissue Complica
Novel Oral Mucosal Surface Organ at Risk, Clinical Oncology (2016), httptarget volume (in patients with oral tongue cancers), when
the spatial location of mucositis was included in the toxicity
scoring system [46]. Although there has been some evi-
dence of increased mucositis with the use of concurrent
chemotherapy [45,47], our results, in agreement with
several other studies [48,49], did not support a strong as-
sociation between concurrent chemotherapy and severe
mucositis.
Our study possesses several limitations. We did not have
access to data pertaining to all of the covariates (for
example, genetic polymorphisms [50], tobacco and alcohol)
in the published studies and, so, were unable to attempt to
replicate all of their ﬁndings using our data. Moreover,
competing dynamic biological processes govern the onset,
progression and resolution of mucositis [28]. Substantial
improvements in predictive performance may require
relevant data relating to those processes. We recommend
that, in the future, investigators should endeavour to
generate NTCP models featuring both relevant biological
data (for example [51]) and a sufﬁciently detailed descrip-
tion of the radiotherapy dose distribution (such as that used
in this study). Furthermore, the dose distribution was
described using the dose calculated on planning computed
tomography scans, which is an approximation of the
delivered dose, probably featuring inaccuracies due to
interfraction motion and patient positioning errors. Image-
guided radiotherapy images were unavailable for many of
the patients in this study so dose accumulation [52] could
not be carried out.Conclusions
We determined that using a novel MSC OAR did not
improve the predictive performance of severe acute
mucositis NTCP models. Exploring dose-response associ-
ations using both OCC and MSC OARs led us to recommend
that radiotherapy planning protocols should prioritise the
reduction of the volumes of oral mucosa receiving high
and intermediate doses, rather than reducing the mean
dose.
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Clinical trials making up the dataset
Trial Patients
available
Primary
disease site
Radiation
therapy
technique
Radiation therapy dose-
fractionation
Concurrent
chemotherapy
COSTAR (phase III,
multicentre) [23]
78 Parotid gland Unilateral;
conventional,
IMRT
65 Gy/30 fractions (deﬁnitive
radiotherapy), 60 Gy/30
fractions (postoperative
radiotherapy)
No
PARSPORT
(phase III,
multicentre) [17]
71 Oropharynx,
hypopharynx
Bilateral;
conventional
IMRT
65 Gy/30 fractions (deﬁnitive
radiotherapy), 60 Gy/30
fractions (postoperative
radiotherapy)
No
Dose escalation
(phase II, single centre)
[18,21]
30 Larynx,
hypopharynx
Bilateral;
IMRT
67.2 Gy/28 fractions, 63 Gy/28
fractions
Yes
Midline
(phase II, single
centre) [19]
117 Oropharynx Bilateral;
IMRT
65 Gy/30 fractions (deﬁnitive
radiotherapy), 60 Gy/30
fractions (postoperative
radiotherapy)
Yes
Nasopharynx
(phase II, single
centre) [20]
36 Nasopharynx Bilateral;
IMRT
65 Gy/30 fractions (deﬁnitive
radiotherapy), 60 Gy/30
fractions (postoperative
radiotherapy)
Yes
Unknown primary
(phase II, single
centre) [22]
19 Unknown primary Bilateral;
IMRT
65 Gy/30 fractions (deﬁnitive
radiotherapy), 60 Gy/30
fractions (postoperative
radiotherapy)
Yes
IMRT, intensity-modulated radiotherapy; unilateral, treatment delivered to ipsilateral parotid bed only; bilateral, treatment delivered to
ipsilateral and contralateral mucosa of relevant subsite (e.g. nasopharynx, oropharynx or larynx).Appendix B. Strategy for Handling Missing
Data
If weekly toxicity data are incomplete this can lead to
assignment of an incorrect peak toxicity grade. For example,
consider a patient who has grade 1 toxicity for weeks 1e3,
grade 2 toxicity for weeks 4 and 5, missing toxicity week 6
and 1 week after treatment and grade 2 toxicity from 2
weeks after radiotherapy to8weeks after radiotherapy. They
would be assigned a peak grade of 2. However, they may, in
fact, have experienced grade 3 toxicity, which was not
scored, as they were unable to attend their follow-up ap-
pointments. This would introduce an error into the analysis.
As this type of error can only lead to peak toxicity being
under-scored and not over-scored it could introduce bias.
Therefore, in an attempt to reduce bias at the expense of
statistical power, patients with any missing toxicity scores
and a peak score below 3 were excluded from the analysis.
Missing toxicity data were not imputed as many patients
(with full toxicity data) with peak toxicity of grade 3 were
only scored as grade 3 for 1 week. We previously investi-
gated the effects of imputing missing toxicity measure-
ments, where there were non-consecutive missing values
and found that this made little difference [13]. Patients withPlease cite this article in press as: Dean JA, et al., Normal Tissue Complica
Novel Oral Mucosal Surface Organ at Risk, Clinical Oncology (2016), httpsome missing toxicity measurements, but at least one
measurement scored as grade 3 were included as they must
have a peak grade of 3 or higher. It should be noted that
retaining patients with missing data, but having a peak
grade of 3 skews the apparent incidences of peak toxicity
grades. Therewas a general trend that dataweremore likely
to be missing around the middle to the end of treatment,
which was when the peak grade of toxicity tended to occur.
It should be noted that our approach to handling missing
data might still result in bias. Where there are missing data
there is always a risk of bias, whichever method for
handling missing data is used. This is particularly true
where the data are not missing at random, as is suggested
by the pattern of missing data in this dataset. Ultimately, the
performance of the model, including any bias introduced by
the missing data handling strategy, should be assessed by
external validation.Appendix C. Example of Three-
dimensional Moment Invariants
Figure C1 shows oral cavity dose distributions for one
patient receiving bilateral irradiation and another receiving
unilateral irradiation.tion Probability (NTCP) Modelling of Severe Acute Mucositis using a
://dx.doi.org/10.1016/j.clon.2016.12.001
J.A. Dean et al. / Clinical Oncology xxx (2016) 1e11 9Fig C1. Example oral cavity dose distributions for pa-
tients receiving bilateral (top) and unilateral (bottom)
irradiation. Sup, superior; inf, inferior; ant, anterior; post,
posterior. The corresponding three-dimensional moment
invariants for these patients are given in Figure C2.Fig C2. Example three-dimensional moment invariants
for patients receiving bilateral (red) and unilateral (blue)
irradiation.Appendix D. Hyper-parameters for Cross-
validated Grid Search
 PLR: regularisation ¼ {LASSO (l1), ridge (l2)}; inverse
regularisation strength (C) ¼ {0.001, 0.01, 0.1, 1.0, 10.0,
100.0, 1000.0}.
 RFC: number of estimators ¼ 1000; maximum
depth¼ {5, 10,15, 20}; maximum features¼ {number of
features, number of features/2, square root of number of
features}.Please cite this article in press as: Dean JA, et al., Normal Tissue Complica
Novel Oral Mucosal Surface Organ at Risk, Clinical Oncology (2016), httpAppendix E. Correlation Matrix
Figure E1 shows the correlation matrix of the covariates
and mucositis severity.Fig E1. Correlation matrix of the variables included in the
modelling. The colour scale shows the Spearman correla-
tion coefﬁcients between the variables. deﬁnitiveRT, deﬁn-
itive radiation therapy (versus postoperative radiation
therapy); indChemo, induction chemotherapy; noCon-
Chemo, no concurrent chemotherapy; cisCarbo, one cycle of
cisplatin followed by one cycle of carboplatin; OCC-PM, oral
cavity contours and pharyngeal mucosa organ at risk; MSC-
PM, mucosal surface contours and pharyngeal mucosa or-
gan at risk; Vx, volume of organ receiving x cGy of radiation
per fraction; etaxyz, three-dimensional moment invarianttion Probability (NTCP) Modelling of Severe Acute Mucositis using a
://dx.doi.org/10.1016/j.clon.2016.12.001
J.A. Dean et al. / Clinical Oncology xxx (2016) 1e1110of order x in the lefteright direction, y in the ante-
rioreposterior direction and z in superioreinferior direc-
tion; severe acute mucositis, peak acute mucositis severity
(non-severe ¼ 0, severe ¼ 1).References
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